#Accu chek inform ii system professional#

This cookie is native to PHP applications. The cookie is used to remember the user consent for the cookies under the category 'Performance'. This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to store the user consent for the cookies in the category 'Necessary'. This cookie is set by GDPR Cookie Consent plugin. The cookie is used to remember the user consent for the cookies under the category 'Analytics'. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category 'Advertising & Targeting'. These cookies do not store any personal information.Ĭookielawinfo-checkbox-advertising-targeting This category only includes cookies that ensures basic functionalities and security features of the website. Necessary cookies are absolutely essential for the website to function properly. These results transfer quickly through the wireless network to give health care providers actionable information. In addition, new technology allows the meter and test strip to provide accurate test results with no interference limitation from maltose, xylose or oxygen.

#Accu chek inform ii system professional#

The system offers additional features for the hospital healthcare professional including unique patient identifiers to improve the accuracy of patient identification and a durable design to meet stringent new cleaning and disinfecting guidelines. The next-generation technology in the ACCU-CHEK Inform II meter and test strip enables the healthcare professional to obtain test results in just five seconds using a small 0.6 microliter capillary blood sample. With more than 2,750 hospital accounts and 117,000 ACCU-CHEK Inform systems in use in more than 48 countries, Roche leads in the world wide hospital blood glucose market. The system is expected to be available in the U.S. In 2011 a total of 25.8 million adults and children in the U.S.

The US is the world’s key market in hospital blood glucose testing.

healthcare professionals new capabilities to help ensure the accuracy of test results, streamline data communications and provide optimal patient care.” “ACCU-CHEK systems have been proven in hospitals around the world and this next-generation wireless system sets a new standard by offering U.S. “Accuracy and patient safety are the foremost concerns for blood glucose testing in hospitals and other point-of-care settings,” said Roland Diggelmann, chief operating officer at Roche Diagnostics. The system utilizes new patented technology to deliver improved accuracy and enables automatic real-time wireless transfer of patient data between hospital medical staff and the laboratory. The ACCU-CHEK Inform II system offers healthcare professionals the first truly wireless hospital blood glucose device. Food and Drug Administration (FDA) for the ACCU-CHEK Inform II system, a next-generation blood glucose monitor for hospital point-of-care testing. Roche (SIX: RO, ROG OTCQX: RHHBY) announced today that it has received clearance from the U.S.